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1. Introduction
The first series of patients treated with the endovascular technique for descending thoracic
aortic aneurysm (DTAA) was published by Dake et al in 1994 [1]. Since then, the use of en‐
dografts has been affirmed as a valid alternative to traditional surgery, above all in elderly and
high surgical risk patients. The progress of experience has evidenced advantageous immediate
and mid term results, above all when compared with traditional surgery. However, this ad‐
vantage has not been found in results at a distance.
The mobilization of the often extremely tortuous thoracic aorta, which is not supported by
nearby internal organs and which extends into three spacial plains, are factors which determine
through time an extreme strain on materials. This wear and tear can be responsible for stent
rupture, and the evolution of complications such as stent migration and endoleak. Further, the
anatomic contiguity of the bronchi and the esophagus, and the fragility of the diseased thoracic
aortic wall, pose serious doubts on the development of catastrophic complications such as
aorta-bronchial and aorta-esophageal fistula through time.
Aneurysms are distinguished as either true, where the aortic wall is constituted by all 3 layers
(tunica intima, media and adventitia), or false, where only the adventitia and/or a perivascular
connective tissue is present. They are classified according to either the pathogenesis: athero‐
sclerotic (degenerative), post-traumatic, micotic, or inflammatory, or based on the morpholo‐
gy: sacciform or fusiform. The most frequent form of aneurysm is atherosclerotic, with an
incidence of 10 cases per 10,000 adults, of which 30-40% are limited to the descending tract of
the thoracic aorta. [2] The pathogenesis of the descending thoracic aorta is similar to the fre‐
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quent infra-renal aneurysm, and is due to the progressive degeneration of the media. Some
authors indicate treatment for aneurysms of a diameter greater than 5.5 cm, but the universal
indications specify a diameter of greater than or equal to 6 cm. The indications are based on
the annual exponential risk of rupture [3], dissection or death associated with aneurysms
greater than 6 cm reaching 16%. [4] True rupture or radiographic signals of imminent rupture
with associated symptoms, also constitute an absolute indication for treatment.
2. Materials and methods
From May 1995 to July 2012, 170 consecutive patients presented at this centre with thoracic
aortic pathologies which were subsequently treated with endovascular solutions. A total of
109 (64.1%) patients were treated in election, and 61 (35.9%) in emergency. The types of treated
thoracic diseases in election included atherosclerotic aneurysms, chronic dissection and chron‐
ic post-traumatic. In emergency, pathologies included ruptured atherosclerotic aneurysm,
acute dissection, aorto-esophageal fistula (AEF), aorto-bronchial fistula (ABF), acute pseudoa‐
neurysm, acute post-traumatic and penetrating ulcer.
2.1. Patient selection
Patient selection for elective treatment at this centre includes rapid aneurysm expansion (> 10
mm in 1 year) or absolute size. For fusiform aneurysms, the minimum diameter was 5.5 cm,
and for saccular aneurysms a protrusion of at least 2 cm from the disease free aortic wall or a
total aortic size of 5 cm was considered an indication for treatment.
2.2. Emergency patient management
All patients treated in emergency are assisted by a vascular surgeon and an anaesthesiologist
from their presentation through to the operating room. Permissive hypotension is practised
with prudent fluid resuscitation to keep systolic blood pressure around 80 mm Hg, in order
to avoid a recommencement of, or increase in bleeding. Patients are assessed by computed
tomographic angiography (Angio-CT), 5 mm slices. Rupture is defined as visible spilling of
blood outside the aneurysm as evident by Angio-CT images, and in some cases of extreme
urgency, by intra-operative angiography and IVUS. During the Angio-CT scanning process,
the operating room is prepared, in order to further reduce delay.
2.3. Pre-operative evaluation
The patients’ anatomic suitability for emergency TEVAR is determined by Angio-CT. The
maximum time taken to execute an Angio-CT in emergency is between 5 - 7 minutes at this
centre (total time delay of 15 – 20 minutes). The diameter and length of the aneurysms are
evaluated directly by the vascular surgeon from the screen. Transferred patients from other
hospitals, with previously performed CT scans, are evaluated during patient transport, with
images delivered via a diacom intranet system.
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Elective patients are evaluated for TEVAR suitability according to the most appropriate mo‐
dality:
• Computed tomographic angiography (Angio-CT)
The volumetric angio-CT (Angio-CTV) is currently considered the best diagnostic tool for the
evaluation of the aorta and its branches. [5-6] The Angio-CTV is non invasive, has a high spatial
resolution and densitometry, which allows the study of the vessels on any spatial plain (the
submillimeter isotropic voxels of the recent Angio-CTV consents the elaboration of the oblique
images to a quality equal to that obtained at axial images).
In endovascular treatment of the DTAA, the Angio-CTV correlated with adequate multi-plain
reconstruction, allows an accurate evaluation of aortic caliber and length, essential information
for the choice of endograft, and the presence of tortuosity, thrombosis and atherosclerotic
lesions. The evaluation of the condition of the accesses is also of fundamental importance.
The limits of the Angio-CTV are common to all imaging methods which utilize ionizing radi‐
ation and iodized contrast mediums:
• exposure to elevated doses of radiation, especially for patients with a long life expectancy
who will require programmed check-ups. Compared to the annual level of natural radiation
a person is exposed to (2 mSv), a single thoracic Angio-CT delivers a dosage equivalent to
that absorbed in 3.6 years (8mSv), which increases to an equivalent of 4.5 years (10 mSv) if
the exam is extended to include the abdomen and the pelvis.
• the risk of allergic reactions to iodized compounds (which is less frequent since the intro‐
duction of non-ionic contrasts)
• nephrotoxicity from iodized contrast, partly resolvable by reducing the toxic chemical com‐
pounds (non ionic iso-osmolar) and the quantity of contrast injected.
• Magnetic resonance angiography (Angio-MR)
Compared with the Angio-CT, the Angio-MR has the advantage of not requiring ionizing
radiation and iodized contrast medium. It therefore represents an alternative for patients with
allergies to contrast mediums and those affected by renal insufficiency. However, the Angio-
MR has an inferior spatial resolution and a reduced capacity to highlight the presence of cal‐
cification compared with Angio-CT. The evaluation of aortic neck and aneurysmal sac
diameters are often less precise, caused by the difficult visualization of the extreme limit of the
aortic wall.
Further, this diagnostic examination cannot be performed in patients with iron magnetic de‐
vices (pace-maker, metallic acoustic devices, vascular ocular clips. etc...), and is contra-indi‐
cated for patients with grave renal insufficiency (GFR <30 ml/min/1.73m2) due to the risk of
systemic nephrogenic fibrosis onset associated with the administration of gadolinium. Com‐
pared to the Angio-CT, this examination methodology is less common, more costly and more
time consuming, and therefore is less accessible to patients.
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2.4. The TEVAR procedure
All TEVAR procedures are performed in a dedicated vascular operating room equipped with
mobile C-Arm (OEC 9800, GE Medical System, Salt Lake City, UT, USA ), IVUS (Volcano s5,
Rancho Cordova, CA, USA) and eco-duplex scanner (Esaote AU 5, Genova, Italy ). Our TEVAR
team includes 3 vascular surgeons (at least 2 endovascular experts), an anaesthesiologist, an
endovascular trained operating room nurse and a radiological technician.
CSF drainage is applied selectively in patients with previous or contemporary AAA treatment,
programmed long coverage of the aortic tract (≥20cm), and coverage of the distal tract beyond
T10-T12. In the case of a short or absent proximal neck which would require the coverage of
the left subclavian artery, reimplantation (the preferred technique) or a bypass is performed
pre-operatively. A preventive retrograde re-vascularization of the visceral vessels (i.e. tripode
or mesenteric or renal arteries) is performed in cases of short distal neck to ensure adequate
distal sealing.
In most cases, arterial access is obtained through the surgical exposure of both femoral or
omeral arteries. Intra-operative angiography is performed manually through an introducer
sheath inserted from the contro-lateral artery to the side chosen for the deployment of the
endograft. The angiography outlines exactly the position of the supra-aortic vessels, which are
then marked directly by the vascular surgeon on the C-Arm screen.
Following the insertion of a super-stiff guide wire, the endograft is deployed. Completion
angiography confirms adequate proximal and distal fixation and identifies any endoleak.
When required, a post-dilation is executed with a compliant balloon.
2.5. Endograft selection
The increasing frequency of DTAA has generated an intensification in endograft manufactur‐
ers interest, determining a technological breakthrough in the presentation of increasingly re‐
fined and better performing devices, each with an individual peculiarity. Nevertheless, the
ideal endograft still does not exist and a single endograft has not demonstrated a clear supe‐
riority over another.
In selecting an endograft, some fundamental principles apply which should always be re‐
spected.
• An oversizing of more than 10 - 15% should not be performed. This is most important in
order to reduce the risk of aorto-esophageal and aorto-bronchial fistulas. However, to date
there are no studies which have demonstrated that the adoption of oversizing greater than
15% to be correlated with the above mentioned complications.
• In the case of a measurement discrepancy of greater than 10% between the proximal and
distal necks, the selection of a tapered endograft is advised.
• For necks with diameters inferior to 20 mm, the use of an endograft with an uncovered
proximal or distal end with the positioning of the device either at the emergence of the
epiaortic or the celiac-mesenteric vessels, according to the case.
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• Where possible, the use of a single segment is preferred to the “telescopic technique” in
order to avoid type III endoleak from segment disconnection. In the case of multiple seg‐
ments being utilized, the overlapping should be at least 5 cm.
The first generation of endografts were Stentor (Min Tec, La Ciotat, France), Vanguard (Boston
Scientific Corp., Natick, MA), Aneurx (Medtronic Vascular, Santa Rosa, CA, USA). The en‐
dografts recently used in the study were commercially available, supplied by Talent (Med‐
tronic Vascular, Santa Rosa, CA, USA), Excluder and TAG device (W.L. Gore and Associates,
Inc., Flagstaff, AZ, USA), Zenith TX2 (Cook, Inc., Bloomington, IN, USA), Endofit (Endomed,
Phoenix, AZ, USA) and Relay (Bolton Medical Inc., Sunrise, FL, USA).
2.6. Data collection
Patients' clinical information is collected prospectively in a dedicated database, and were ret‐
rospectively evaluated for this study.
2.7. Follow-up protocol
The post-discharge TEVAR follow-up scheme at this centre consists of routine Angio-CT at 3,
6 and 12 months, and annually thereafter in the absence of symptoms. Plain radiographs are
performed at 6 months, and annually thereafter.
3. Results
From May 1995 to July 2012, 170 consecutive patients with various thoracic aortic pathologies
were treated with endovascular solutions at this centre. A total of 109 (64.1%) patients were
treated in election for DTA diseases, and 61 (35.9%) in emergency (Table 1). Patient mean age
was 73.78 yrs old.
CSF drainage was used in 16 (9.4%) patients. A reimplantation or bypass of the left subclavian
artery was performed pre-operatively for a total of 31 (18.2%) patients. In 5 (2.9%) cases, a
preventive retrograde re-vascularization of the visceral vessels was performed.
Complications following treatment are outlined in Table 2. The most common intra-operative
complications were access associated (15.9%). Neurological complications were observed in
7%. 30 day mortality was reported at 14.1%, with the majority of the deaths occurring among
the patients treated in emergency (29.5%).
Late complications included a rate of endoleak of 20% (24 patients of the 34 cases had recurrent
endoleak), rupture in 3.5%, 2 aorto-esophageal fistulas (AEF) and single cases of aorto-bron‐
chial fistula and infection.
Reinterventions were required in 21.1%. Most were treated with endovascular solutions
(91.7%). Table 3 outlines the complications for which a reintervention was required and the
modality of intervention.
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4. Discussion
Various studies which compare thoracic endovascular aortic aneurysm repair (TEVAR) to
traditional surgery for DTAA in literature report superior results for endovascular treatment,
most importantly in terms of post-operative complication rates and length of hospital stay.
A meta-analysis published in 2010 [7] including 38 comparative studies and 4 registries (5,888
patients) revealed a significant reduction in mortality for TEVAR (5.8% vs 13.8%, p<0.00001,
OR=0.44), neurological, renal, respiratory and cardiological complications (41.4% vs 69.3%,
p<0.001, OR=0.19) and length of hospital stay (7 days less for TEVAR).
A meta-analysis comparing the two techniques by Walsh et al. [8] including 17 published
series, with a total of 1,109 patients, also concluded a significant reduction in mortality
(p=0.005, OR=0.25) and neurological complications (p=0.0013, OR=0.28) for TEVAR.
A study published in 2010 [9] compared data extracted from the NIS (National Inpatient Sam‐
ple) database with data of 11,669 patients. This study found that the mortality rates were iden‐
tical for both TEVAR and traditional surgery (2.3%), even though the mean age of TEVAR
patients was significantly higher (69.5 vs 60.2 yrs, p<0.001). Significant reductions were also
found for TEVAR in terms of post-operative complications (60%, p<0.001, OR=0.39) and length
of hospital stay (p<0.001).
4.1. Complications associated with endovascular treatment
4.1.1. Access complications
Carpenter et al. [10] reported that inadequate accesses are responsible for roughly 50% of the
cases of ineligibility for TEVAR treatment.
Damage of access vessels continues to the greatest cause of grave comorbidities and even death,
correlated to endovascular treatment of thoracic aorta pathologies. [11-12] It has been esti‐
mated that access related problems occur in around 28% of cases. [13-14] This is principally
due to three reasons. The first reasons is that thoracic endografts generally require introducers
with large calibers (20-25 Fr.), with external diameters between 22 and 27 Fr. Secondly, unlike
the aneurysmatic pathology in the abdominal aorta, over 30% of the population with DTAA
is female who generally present with vessels of smaller diameters. [15] The third reason is that
the often advanced aged patients present with atherosclerotic steno-obstructive lesions and
accentuated tortuosity, above all at the iliac axes.
In cases of small caliber vessels, the phase of the removal of the introducer is particularly
crucial, which can provoke rupture and in some cases the complete detachment of the iliac
artery. [16]
The preoperative examination is therefore of fundamental importance in order to plan the best
access site and to be ready during the intervention for alternative operative strategies if nec‐
essary. The femoral access is suitable in 70-85% of cases, [11, 17] although in doubtful cases,
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the selection of a more proximal access site (iliac or aortic in extreme cases), also with the
assitance of another graft, is recommended to avoid potential grave complications.
Another useful strategy includes the use of a Coons dilator (Cook Medical, Bloomington,
IN) with progressively increasing diameters, incrementing 2 Fr at a time. The dilator enables
both the testing of a possible passage and the progressive dilation of the artery to a diameter
which adequately allows the passage of the endograft. It must also be underlined that, in
cases  of  difficult  accesses,  an  angiographic  evaluation  of  the  iliac  arteries  is  absolutely
necessary.
4.1.2. Neurological complications
Paraplegia and stroke represent the most devastating complications associated with the treat‐
ment of thoracic aorta pathologies.
Compared to traditional surgery, endovascular treatment appears to have significantly re‐
duced the global incidence of paraplegia. This advantage is of particular relevance in the treat‐
ment of acute Stanford type B dissections, where the incidence associated with traditional
surgery is between 14 - 19% [18-19]. Conversely, for the treatment of isolated descending
thoracic aneurysms, the two treatment techniques have a comparable incidence of paraplegia,
reported to be between 0-4% [20] and 2.5% [21] respectively.
The mechanisms which provoke paraplegia following TEVAR have not been fully identified.
Simultaneous and previous traditional surgery of the abdominal aorta has been associated
with increased risk of paraplegia. [21-23] The medullary vascularization from the lumbar and
hypogastric arteries are important contributors in the risk of paraplegia. [24] Given this infor‐
mation, it is therefore advised by various authors [22,25] to perform eventual treatment of the
abdominal and thoracic aorta in different interventions, so that a gradual establishment of a
collateral medullary vascular circuit can be established. At this centre, in cases where a long
segment of the thoracic aorta is planned to be covered and the hypogastric circulation is com‐
promised, a preventive treatment is routinely performed. Embolization into major intercostal
arteries due to the manipulation of the device in the aortic lumen has also been nominated as
another potential risk factor. Extended coverage of the thoracic aorta has also been proven
[22,26-28] to augment the risk of medullary ischemia. This risk rises further when coverage
includes the region distal to T10. [22, 25, 29]
The EUROSTAR [21] study reported a significantly increased incidence of paraplegia when
three or more endograft segments were used (OR, 3.5; P =.043).
A debated argument is that of the necessity to perform left subclavian revascularization when
the placement of the endograft requires the coverage of the left subclavian artery. The EURO‐
STAR [21] study demonstrated the contribution of the subclavian/left vertebral arteries to the
anterior spinal artery, and that the coverage of which determines an almost 4 times increased
risk of paraplegia (OR, 3.9; P =.027). At this centre, with the exception of emergency cases, a
preventative transposition of the subclavian artery is performed in all cases where treatment
would require it to be covered.
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Chiesa et al. [25] highlighted the importance of arterial pressure in the post-operative period:
medium pressure values of 70 mmHg are associated with an increased risk of medullary is‐
chemia. Other correlated factors include the female gender and renal insufficiency.
The causes of late onset paraplegia are more difficult to identify. A possible cause could be the
onset of a secondary medullary edema due to damage such as reperfusion ischemia, which
could in some cases reduce the medullary perfusion. Another possible cause could also be
linked to long periods of post-operative hypotension.
The principal prevention method of medullary ischemia is cerebral spinal fluid (CSF) drainage.
The use of this method however, should be weighted against the risk of complications asso‐
ciated with this procedure, which above all include subdural hematoma and infection. For this
reason, and as suggested by other authors, the procedure is reserved for selected cases only in
which a long tract of thoracic aorta is programmed to be covered (>20 cm) or in cases in which
previous traditional surgery or endovascular treatment of the abdominal aorta is evidenced.
Other methods utilized in the surgical environment includes medullary cooling [30] in order
to reduce metabolic activity and increase the tolerance of the medulla to ischemia and the use
of corticosteroids [31] with the aim of reducing edema from revascularization. This method
has not found a use in TEVAR.
The incidence of stroke was reported in a literature review published in 2006 by Sullivan et al.
[32] to be a mean of 2.2%. The EUROSTAR [21] study reported a 3.1% incidence of stroke in
606 patients treated with endografts for all pathologies of the thoracic aorta. It is commonly
accepted that the cause of stroke during TEVAR is related to embolization caused by the ma‐
nipulation of catheters and guide wires in the “dirty” aortic arch, rather than a base of hypo‐
perfusion. [33-34]
The EUROSTAR [21] identified two significant risk factors for stroke: the duration of the pro‐
cedure > 2.6 hours and female gender. Whilst the duration of the procedure is obviously con‐
nected to a greater manipulation of the guide wire and catheters in the aortic arch, the reasons
explaining as to why females are more likely to develop a stroke is more difficult to understand.
An hypothesized explanation is that in female patients the atherosclerotic pathology is often
more advanced.
It can be deduced that the most effective mode of stroke prevention is an accurate pre-operative
evaluation of the aortic arch, a careful manipulation of the catheters and guide wires attempt‐
ing to limit maneuvers to those of absolute necessity, and an extensive operative strategy plan
devised to reduce to a minimum the operative time.
4.1.3. Endoleak
Endoleak is the most frequent motive for reintervention following TEVAR. [35]
The rates of endoleak reported in literature vary and depend upon the type of pathology
treated,  and  the  length  of  the  follow-up.  Parmer  et  al.  [36]  reported  an  endoleak  inci‐
dence of 29% at an average follow-up of 17 months, Ellozy et al. [37] published an incidence
of 18% at roughly 15 months, and the Gore-TAG trial [38] reported only 10.6% at 5 years.
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The EUROSTAR study [35] declared a 6.5% rate of need for secondary intervention due to
endoleak  at  2  years.  Beyond  single  experiences,  the  reasoning  behind  this  frequent
complication can be explained by two fundamental factors: the prominent mobility and the
frequent tortuosity of the thoracic aorta. Both of these factors force the endograft, and can
provoke migration through time, disconnection and even rupture.
Parmer et al. [36] also evidenced some factors which are combined with the development of
endoleak: male gender, larger diameter aneurysms, coverage of a long portion of the thoracic
aorta and the usage of multiple endograft segments.
Among the various types of endoleak, the most frequent is type I proximal, reported as having
an incidence in literature ranging between 0 and 44%. [39-41] The extreme variation in range
can be explained by the different anatomical complexities in the aneurysms treated and there‐
fore in the selection criteria. It is noted that the treatment of an isolated relatively small aneur‐
ysm situated in the rectilinear descending thoracic aorta, is relatively simple to treat and the
development of a complication is relatively rare. Conversely, the treatment of an aneurysm
which includes a part of the aortic arch is more complex and the results are less convincing.
We believe that in the circumstances of complex anatomies including the aortic arch, it is nec‐
essary to construct a straight neck of at least 2 cm, which may include a by-pass or a transpo‐
sition of the epi-aortic branches, in the hope of achieving aneurysm exclusion which will
endure through time.
Type II endoleak are less common in the thoracic aorta compared to the incidence observed in
the abdominal aortic region. In some cases, post-deployment angiography can evidence the
patency of bronchial and intercostal arteries, but these arteries generally develop spontaneous
thrombosis and do not require treatment.
Type III endoleak are the second most common form of endoleak. The extreme mobility of the
thoracic aorta and its frequent tortuosity, especially found in large caliber aneurysms, can
invoke through time the disconnection of the endograft segments and in some cases wear and
tear which can lead to graft rupture. Experience has enabled the reduction in the incidence of
type III endoleak, through increasing the length of device overlap in the case of multiple seg‐
ments, which at this centre we believe should not be less than 5 cm, and using longer endografts
rather than multiple shorter segments.
4.1.4. Aneurysm rupture
Avoiding aneurysm rupture is the ultimate objective of endovascular treatment. The percent‐
age of rupture following endovascular treatment of abdominal aortic aneurysms (AAA) has
been estimated to be around 1%.
The Stanford University group [42] reported their experience of TEVAR with a “custom-made”
endograft claiming a rate of rupture at a distance of 10.7%, and a mortality rate of 91% at an
average follow-up of 54 months. The EUROSTAR study [35] reported 2 cases of rupture at a
distance of 12 months in 443 patients (0.5%). Other smaller experiences in literature with fol‐
low-ups ranging from 15 - 40 months presented a percentage of rupture at a distance between
1.6% and 6%. [37,43,44]
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4.1.5. Aorto-Esophageal Fistula (AEF) and Aorto-Bronchial Fistula (ABF)
The AEF and the ABF are grave complications, which are almost always fatal and whose
incidence is yet to be clearly defined. The Stanford University study [42], published in 2004,
revealed a rate of AEF/ABF of 3%. Eggebrecht [45] also reported in 2004 an incidence equal to
5%, which were fatal in 100% of cases. Other cases of AEF/ABF following TEVAR have also
been reported in more recent experiences. [38,43,46-47]
The anatomical proximity of the bronchi and the esophagus to the aorta is a factor which
influences the incidence of this disastrous complication through time, due to the associated
mechanical stress exercised by the endograft on the diseased aortic wall.
The use of restricted oversizing (about 10%) to reduce the mechanical stress on the aortic wall
may theoretically reduce the incidence of these complications. However, this theory has not
yet been proven.
4.2. Emergency treatment for ruptured thoracic aortic aneurysms
The annual incidence of rupture of the thoracic aortic aneurysm has been estimated to be at 5
cases per 100,000 inhabitants. [48-49] Around 30% of all the ruptured thoracic aortic aneurysms
are localized in the descending aorta (rDTAA), with the remaining 70 % involving the arch
and the ascending thoracic aorta. RDTAA represents a catastrophic event with a global
mortality rate estimated to be up to 97%. [48]
In the few patients who arrive to the emergency department alive, traditional surgery has an
ulterior mortality rate of 45% and a rate of systemic complications of around 50%. [50]
Endovascular treatment for rDTAA requires an endovascular emergency service with
dedicated technical and nursing personnel combined with a surgical, anesthesiological and
radiological team with knowledge and experience of endovascular materials. This preparation
also demands the availability of advanced radiological equipment (eg. Angio CT) and an
endovascular team 24hr/24hr for adequate diagnosis and treatment. The endovascular team
must also be competent in traditional surgical techniques, so as to be able to treat different
cases with the most appropriate surgical method. The operation room must also be equipped
for an endovascular procedure, with high quality radiological and ultrasonographic machines
(such as a portable C-Arm angiography and intravascular ultrasound (IVUS) and must have
a large warehouse of basic endovascular materials available.
A meta-analysis [51] comparing traditional surgery and TEVAR for rDTAA included 859
patients and revealed significantly reduced mortality and paraplegia rates in favour of TEVAR.
Mortality rates (11.4% vs 26.5%, p=0.13) favoring endovascular treatment were also reported
by Patel et al. [52] in a comparative study.
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5. Conclusion
Various studies have demonstrated a reduction in intra-operative mortality and neurological
complications associated with endovascular treatment for DTAA pathologies compared to
traditional surgery.
Technical improvements in catheters, specifically in terms of flexibility, have enabled the re‐
duction in access related complications and the extension of the patient population to include
those with more complex anatomies in terms of tortuosity. Mid and long term complications
are still frequent, but are often able to be treated with ulterior endovascular procedures. A
substantial rate of complications, such as rupture and AEF/ABF, are frequently fatal and often
underestimated, especially in the case of fistulas.
At this centre however, endovascular treatment is considered the first choice treatment in
emergency for rDTAA and in elderly patients and/or patients at high surgical risk. For patients
with a long life expectancy, traditional surgery is currently our preferred treatment.
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